Original Article

Beneficial Effect of Moderately Increasing Hypothermic Machine Perfusion Pressure on Donor after Cardiac Death Renal Transplantation

Chen-Guang Ding1,2, Pu-Xun Tian1,2, Xiao-Ming Ding1,2, He-Li Xiang1,2, Yang Li1,2, Xiao-Hui Tian1,2, Feng Han1,2, Qian-Hui Tai1,2, Qian-Long Liu1,2, Jin Zheng1,2, Wu-Jun Xue1,2

1Department of Renal Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
2Institute of Organ Transplantation, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China

Abstract

Background: Vascular resistance and flow rate during hypothermic machine perfusion (HMP) of kidneys is correlated with graft function. We aimed to determine the effects of increasing HMP pressure versus maintaining the initial pressure on kidney transplantation outcomes.

Methods: We retrospectively reviewed the data of 76 primary transplantation patients who received HMP-preserved kidneys from 48 donors after cardiac death between September 1, 2013, and August 31, 2015. HMP pressure was increased from 30 to 40 mmHg (1 mmHg = 0.133 kPa) in kidneys with poor flow and/or vascular resistance (increased pressure [IP] group; 36 patients); otherwise, the initial pressure was maintained (constant pressure group; 40 patients). Finally, the clinical characteristics and transplantation outcomes in both groups were assessed.

Results: Delayed graft function (DGF) incidence, 1-year allograft, patient survival, kidney function recovery time, and serum creatinine level on day 30 were similar in both groups, with improved flow and resistance in the IP group. Among patients with DGF, kidney function recovery time and DGF duration were ameliorated in the IP group. Multivariate logistic regression analysis revealed that donor hypertension (odds ratio [OR]: 1.43, 95% confidence interval [CI]: 1.02–2.06, \( P = 0.035 \)), donor terminal serum creatinine (OR: 1.27, 95% CI: 1.06–1.62, \( P = 0.023 \)), warm ischemic time (OR: 3.45, 95% CI: 1.97–6.37, \( P = 0.002 \)), and terminal resistance (OR: 3.12, 95% CI: 1.76–6.09, \( P = 0.012 \)) were independent predictors of DGF. Cox proportional hazards analysis showed that terminal resistance (hazard ratio: 2.06, 95% CI: 1.32–5.16, \( P = 0.032 \)) significantly affected graft survival.

Conclusion: Increased HMP pressure improves graft perfusion but does not affect DGF incidence or 1-year graft survival.

Key words: Delayed Graft Function; Donor after Cardiac Death; Hypothermic Machine Perfusion; Kidney Transplantation

Introduction

In recent years, donors after cardiac death (DCDs) have become the major source of organs for transplantation in China.1,2 Nevertheless, studies in Europe, the USA,3–5 and China6,7 have shown that the transplantation of kidneys obtained from DCDs is associated with a high incidence of delayed graft function (DGF), as well as early graft dysfunction and failure. Indeed, DGF increases the risk of graft rejection and decreases graft survival.8

Static cold storage is considered the standard method of kidney preservation since the 1970s. Studies have suggested that compared with static cold storage, hypothermic machine perfusion (HMP) of kidneys obtained from DCDs is associated with improved early function and improved graft survival.9–12 which remains controversial.13,14 Comprehensive meta-analyses have confirmed a significant

Access this article online

Quick Response Code:

Website: www.cmj.org

DOI: 10.4103/0366-6999.245274

Address for correspondence: Prof. Wu-Jun Xue, Department of Renal Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
Institute of Organ Transplantation, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China
E-Mail: xwujun@126.com

Received: 03-05-2018 Edited by: Qiang Shi
How to cite this article: Ding CG, Tian PX, Ding XM, Xiang HL, Li Y, Tian XH, Han F, Tai QH, Liu QL, Zheng J, Xue WJ. Beneficial Effect of Moderately Increasing Hypothermic Machine Perfusion Pressure on Donor after Cardiac Death Renal Transplantation. Chin Med J 2018;131:2676-82.
reduction in the risk of DGF when kidneys obtained from DCDs are preserved using HMP rather than static cold storage.\textsuperscript{15,16} Furthermore, HMP enables the assessment of graft viability and quality prior to transplantation and might also enable the repair of potential grafts.\textsuperscript{17-19} Therefore, various HMP parameters have been evaluated in order to optimize graft quality prior to transplantation; such parameters include the perfusate flow rate, vascular resistance, and perfusate pressure, as well as the changes in these parameters during persistent perfusion.\textsuperscript{17,20,21} Elevated vascular resistance and reduced perfusate flow rate in potential kidney grafts may be corrected by increasing the perfusate pressure\textsuperscript{17,20,21} However, the ideal pressure required to perfuse donor kidneys has yet to be determined.

We therefore retrospectively analyzed the effects of two different HMP pressures on the outcomes of primary transplantation patients who received kidneys harvested from DCDs. We also studied whether the renal transplant recipients could benefit from increased perfusion pressure.

**Methods**

**Ethical approval**

The local institutional review board of the First Affiliated Hospital of Xi’an Jiaotong University approved the study protocol, which was in compliance with the provisions of the current Declaration of Helsinki principles and good clinical practice guidelines. All patients provided written informed consent for participation in the study and to have their medical data used for research purposes.

**Patient population**

We retrospectively reviewed the effects of all consecutive Chinese patients aged between 18 and 65 years who underwent primary kidney transplantation with HMP-preserved DCD kidneys at The First Affiliated Hospital of Xi’an Jiaotong University between September 1, 2013 and August 31, 2015. Patients were excluded from the study if they (a) had undergone re-transplantation, received an organ other than a kidney, or showed loss of function of the transplanted kidney induced by surgical factors; (b) had a positive cross-match or panel-reactive antibody (over 30%); (c) had an active infection, hepatitis, or abnormal hepatic function; (d) had severe gastrointestinal disorders (such as diarrhea or active peptic ulcer disease) or uncontrolled diabetes mellitus before transplantation; (e) had leukopenia (leukocytes <3000/mm\(^3\)), thrombocytopenia (platelets <100,000/mm\(^3\)), or severe anemia (hemoglobin <60 g/L); (f) terminal flow rate <60 ml/min and/or terminal vascular resistance >0.6 mmHg ml\(^{-1}\)·min\(^{-1}\) at 15 min, the perfusion pressure was increased to 40 mmHg (IP group). Otherwise, the perfusion pressure was maintained at 30 mmHg (CP group). This approach was used at our transplantation center during the study period, based on previous literature\textsuperscript{17,20,21} and our clinical experience.

**Immunosuppressive treatments**

A triple immunosuppressive regimen was used in all patients, consisting of tacrolimus (0.06 mg·kg\(^{-1}\)·d\(^{-1}\)) or cyclosporine A (3.5 mg·kg\(^{-1}\)·d\(^{-1}\)) combined with mycophenolate mofetil (2 g/day) or mycophenolic acid (1440 mg/d) and prednisone (10 mg/d). In addition, all patients received thymoglobulin (Genzyme, Waterford, Ireland) at a dose of 1.25 mg·kg\(^{-1}\)·d\(^{-1}\) for 4 days, starting perioperatively.

**Clinical assessments**

Early graft function was assessed as follows: (a) DGF was defined as the requirement of dialysis during the 1\(^{st}\) postoperative week; (b) the duration of DGF was the interval between the transplantation and last dialysis session; (c) slow graft function (SGF) was identified in patients who did not have DGF but whose serum creatinine (sCr) levels remained >2 mg/dl (177 mmol/L) by postoperative day 7; (d) immediate graft function (IGF) was identified in patients who did not have DGF or SGF and whose sCr levels were <2 mg/dl by postoperative day 7; and (e) kidney function recovery time was the interval from transplantation to recorded sCr levels <2 mg/dl.

Acute renal allograft rejection episodes were suspected with increased sCr levels in the presence of clinical findings such as reduced urine output, weight gain, increased blood pressure, and graft tenderness. A core biopsy was performed for suspected acute rejection. All biopsy specimens were assessed by local pathologists and graded according to the Banff 2013 classification.\textsuperscript{22} The incidence, duration, and treatment of acute rejection were noted during the first 12 months after transplantation. Allograft biopsies were performed only for clinically indicated causes or every group (36 patients). Patients were allocated kidney grafts by the attending physicians according to standard clinical practice guidelines, and 28 kidneys in both the CP and IP groups were from the same donors (left or right). The kidney grafts were provided by the Coordination Group of the Shaanxi Red Cross Organization and harvested from DCDs classified as controlled or uncontrolled DCDs according to the Maastricht classification. All kidneys were preserved in a Lifeport kidney transporter (Organ Recovery Systems, Chicago, IL, USA) and perfused with the kidney perfusion solution KPS-1. The initial pump pressure was set to 30 mmHg. Based on our previous observations, we found that perfusion parameters were unstable 15 min ago. After 15 min, the perfusion parameters began to change slowly. Therefore, the following perfusion parameters were measured 15 min after the beginning of perfusion: flow rate, vascular resistance, perfusion pressure, and trap temperature. In case of flow rate <60 ml/min and/or vascular resistance >0.6 mmHg ml\(^{-1}\)·min\(^{-1}\) at 15 min, the perfusion pressure was increased to 40 mmHg (IP group). Otherwise, the perfusion pressure was maintained at 30 mmHg (CP group). This approach was used at our transplantation center during the study period, based on previous literature\textsuperscript{17,20,21} and our clinical experience.
7–10 days in recipients with DGF to exclude acute rejection. Biopsy-proven acute rejection episodes were treated with 500 mg methylprednisolone administered intravenously on 3 consecutive days, plus optimized calcineurin inhibitor and mycophenolic acid therapy. Thymoglobulin or rabbit antihuman thymocyte immunoglobulin was administered for 5–10 days in patients with steroid-resistant rejection or early high-grade rejection.\textsuperscript{23,24} Rituxan\textsuperscript{®} (200 mg) was administered for one or two times in patients with antibody-mediated rejection (AMR), plus plasmapheresis and intravenous immunoglobulin.

**Statistical analysis**

Quantitative variables are presented as frequency and percentage and qualitative variables as mean ± standard deviation (SD) or median. Demographic characteristics and the results of the baseline examination data were compared by Student’s t-test or the Mann–Whitney U-test, depending on data normality. Dichotomous data were compared by the Pearson’s Chi-square test or Fisher’s exact test. A multivariate logistic regression model for DGF and a Cox regression model for graft failure were used. Patient and graft survivals were assessed by the Kaplan–Meier method and compared between groups by the log-rank test. All statistical analyses were performed on an intention-to-treat basis. A two-sided $P < 0.05$ was considered statistically significant. All calculations were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Demographic and clinical characteristics of donors and recipients**

The 48 DCDs provided 96 kidneys. Twenty kidneys were excluded. Of these, 2 kidneys were abandoned due to renal abnormalities, 1 due to poor perfusion effect, and 3 due to a perfusion resistance index >0.6 before Lifeport transplantation. In the remaining 14 kidneys, the perfusion resistance index was unable to reach 0.6 within the required time. Therefore, 76 patients received 1 kidney each during the study period. Their demographic and clinical characteristics are shown in Table 1. Of the 76 patients, 40 and 36 were assigned to the CP and IP groups, respectively. There were no significant differences between these two groups with respect to donor and recipient age, duration of pretransplant dialysis, positivity for panel-reactive antibody, number of HLA mismatches, cold ischemic time, warm ischemic time (determined from the beginning of heartbeat to the start of perfusion), primary diseases in recipients, causes of death of donors, sCr levels, body mass index, and DCD Maastricht categories (all $P > 0.05$).

**Hypothermic machine perfusion parameters**

Initial (perfusion for 15 min) and terminal flow rates were 48.3 ± 10.6 ml/min and 76.3 ± 12.7 ml/min, respectively ($P < 0.001$), in the CP group and 47.4 ± 7.5 ml/min and 85.9 ± 14.6 ml/min, respectively ($P < 0.001$), in the IP group. The terminal flow rate was significantly lower in the CP group than in the IP group ($P = 0.003$) [Table 2]. In both groups, initial vascular resistance (perfusion for 15 min) was significantly higher than the terminal resistance ($P < 0.001$) [Table 2]. In addition, terminal resistance was significantly higher in the CP group than in the IP group ($P = 0.023$). The trap temperature and HMP duration did not differ between the two groups.

**Early graft function**

The incidence of DGF did not differ between the CP (27.5%, 11/40 patients) and IP (25.0%, 9/36 patients, $P = 0.805$) groups; the rates of slow and immediate graft function also did not differ between the two groups ($P = 0.412$ and $P = 0.411$, respectively) [Table 3]. Multivariate logistic regression analysis revealed four significant risk factors for DGF, including donor hypertension history (odds ratio [OR]: 1.43, 95% confidence interval [CI]: 1.02–2.06, $P = 0.035$), donor terminal sCr (OR: 1.27, 95% CI: 1.06–1.62, $P = 0.023$), warm ischemic time (OR: 3.45, 95% CI: 1.97–6.37, $P = 0.002$), and terminal vascular resistance (OR: 3.12, 95% CI: 1.76–6.09, $P = 0.012$) [Table 4]. HMP pressure (CP vs. IP; OR: 0.51, 95% CI: 0.22–0.94, $P = 0.250$) and terminal flow (OR: 0.79, 95% CI: 0.47–0.96, $P = 0.053$) [Table 3] did not significantly influence the rate of DGF. Meanwhile, sCr levels at 30 days after transplantation did not differ between the CP (1.47 ± 0.31 mg/dl) and IP (1.39 ± 0.22 mg/dl; $P = 0.203$) [Table 3] groups.

**Kidney function recovery time and delayed graft function duration**

The overall kidney function recovery time did not differ between the CP (18.3 ± 9.1 days) and IP (16.7 ± 8.3 days, $P = 0.427$) groups; however, among patients who developed DGF, the kidney function recovery time was significantly longer in the CP group (25.4 ± 5.1 days) than in the IP group (20.2 ± 4.7 days, $P = 0.031$) [Table 3]. In addition, the duration of DGF was significantly higher in the CP group (15.6 ± 2.4 days) than in the IP group (13.2 ± 2.6 days, $P = 0.046$) [Table 3].

**Acute rejection**

Nine (22.5%) and 7 (19.4%) patients in the CP and IP groups, respectively, developed acute rejection within 1 year of transplantation ($P = 0.744$). Four of the 11 recipients with DGF in the CP group (36.4%) and 3 of the 9 in the IP group (33.3%) developed an acute rejection episode within 1 year of transplantation ($P = 0.742$) [Table 3].

**Graft and patient survival rates**

By the 1-year follow-up assessment, five patients (two cases of AMR did not recover, one case primary nonfunctioning, one case renal artery stenosis, and one case ureteral obstruction in transplanted kidney) in the CP group and four (two cases of AMR did not recover, one case rupture of transplanted kidney, and one case of renal allograft abscess) in the IP group had developed allograft failure. In the same time period, three patients each in the CP (one patient died from cardiovascular disease and two from pulmonary infection) and IP (one
Table 1: Demographic and clinical characteristics of recipients

| Variables                        | CP group (n = 40) | IP group (n = 36) | t or χ²  | P     |
|----------------------------------|------------------|------------------|---------|-------|
| Recipients                        |                  |                  |         |       |
| Age (years), mean ± SD           | 39.1 ± 6.6       | 40.2 ± 7.4       | 0.685*  | 0.495 |
| Gender (male/female), n          | 24/16            | 20/16            | 3.840†  | 0.695 |
| BMI (kg/m²), mean ± SD          | 22.3 ± 4.7       | 22.6 ± 4.2       | 2.021*  | 0.768 |
| Hemodialysis, n (%)              | 37 (92.5)        | 34 (94.4)        | 0.120†  | 0.733 |
| Peritoneal dialysis, n (%)        | 3 (7.5)          | 2 (5.6)          | 0.120†  | 0.903 |
| Dialysis duration (months), mean ± SD | 26.4 ± 3.7 | 28.3 ± 5.3       | 1.793*  | 0.073 |
| Primary disease                  |                  |                  |         |       |
| Chronic GN, n (%)                | 33 (82.5)        | 30 (83.2)        | 1.390†  | 0.923 |
| Diabetic nephropathy, n (%)      | 2 (5.0)          | 2 (5.6)          | 0.010†  | 0.685 |
| IgA nephropathy, n (%)           | 1 (2.5)          | 1 (2.8)          | 0.010†  | 0.521 |
| Other, n (%)                     | 1 (2.5)          | 1 (2.8)          | 0.010†  | 0.521 |
| Primary transplantation, n (%)   | 40 (100)         | 36 (100)         | –       | –     |
| HLA mismatches, mean ± SD        | 2.1 ± 1.3        | 2.2 ± 1.2        | 0.347†  | 0.729 |
| Pretransplant PRA (%), mean ± SD | 2.5 ± 1.2        | 2.3 ± 1.4        | 0.671†  | 0.505 |

*Student’s t-test; †Chi-square test. –: Not applicable; CP: Constant HMP pressure; IP: Increased HMP pressure; BMI: Body mass index; GN: Glomerulonephritis; HN: Hypertensive nephrosclerosis; HLA: Human leukocyte antigen; PRA: Panel-reactive antibody; HMP: Hypothermic machine perfusion.

Table 2: Demographic and clinical characteristics of donors

| Variables                        | CP group (n = 40) | IP group (n = 36) | t or χ²  | P     |
|----------------------------------|------------------|------------------|---------|-------|
| Age (years), mean ± SD           | 45.7 ± 10.4      | 44.9 ± 11.3      | 0.321*  | 0.749 |
| BMI (kg/m²), mean ± SD          | 23.2 ± 4.5       | 23.9 ± 3.7       | 0.736*  | 0.464 |
| Cause of death, n (%)            |                  |                  |         |       |
| Craniocerebral trauma            | 18 (45.0)        | 17 (47.3)        | 0.040†  | 0.846 |
| Cerebrovascular diseases         | 15 (37.5)        | 12 (33.3)        | 0.140†  | 0.705 |
| Anoxic encephalopathy            | 4 (10.0)         | 4 (11.1)         | 0.020†  | 0.828 |
| Other                            | 3 (7.5)          | 3 (8.3)          | 0.020†  | 0.771 |
| Hypertension history, n (%)      | 15 (37.5)        | 13 (36.1)        | 0.020†  | 0.900 |
| sCr (mg/dl), mean ± SD           | 1.42 ± 0.25      | 1.38 ± 0.19      | 0.779†  | 0.439 |
| CIT (h), mean ± SD               | 9.2 ± 2.4        | 9.3 ± 2.1        | 0.192†  | 0.848 |
| WIT (min), mean ± SD             | 11.4 ± 2.6       | 11.6 ± 2.2       | 0.360*  | 0.720 |
| DCD, n (%)                       |                  |                  |         |       |
| Controlled                       | 28 (70.0)        | 29 (80.6)        | 1.130†  | 0.120 |
| Uncontrolled                     | 12 (30.0)        | 7 (19.4)         | 1.130†  | 0.120 |

WIT was calculated from circulatory arrest until the start of cold perfusion. *Student’s t-test; †Chi-square test. –: Not applicable; CP: Constant HMP pressure; IP: Increased HMP pressure; BMI: Body mass index; sCr: Serum creatinine; CIT: Cold ischemic time; WIT: Warm ischemic time; DCD: Donor after cardiac death; HMP: Hypothermic machine perfusion.

Discussion

HMP of kidneys has been deemed superior to static cold storage due to improved perfusion of the microvasculature, decreased aggregation of blood components, mitigated endothelial activation, and reduced inflammatory upregulation.[14‑16] Kidney graft viability and quality cannot be assessed when kidneys are stored on melting ice. In contrast, HMP enables the assessment of graft viability and quality prior to transplantation, as well as the evaluation of perfusion characteristics such as resistance and flow rate. Retrospective evidence suggests that resistance and flow rates during HMP correlate with kidney graft function.[15‑17] Resistance at the end of HMP is considered an independent risk factor for the development of DGF.[15‑17] Increased flow rate may be partially responsible for improved transplantation results. Furthermore, kidneys with higher resistance and lower flow rates have significantly higher discard rates. These two findings substantiate the case for increasing pressure during HMP to improve flow through the kidney. Nevertheless, this method of addressing reduced compliance in the hypothermic setting must be weighed against the risk of increased cold ischemic time, increased warm ischemic time, and increased risk of graft failure. Owing to the low number of graft losses, we considered the following variables of interest: CP versus IP, terminal vascular resistance, donor terminal sCr levels, and warm ischemic time, which were the strongest independent risk factors for graft failure in the current study [Table 5]. In the Cox proportional hazards model, only terminal vascular resistance significantly affected the graft survival rate (hazard ratio: 2.06, 95% CI: 1.32–5.16, P = 0.032) [Table 6].
The present study was undertaken to determine the effects of HMP during which the initial perfusion pressure was maintained versus HMP during which pressure was increased on posttransplant outcomes of DCD kidneys in primary transplant recipients. Postoperative kidney function was judged by assessing the incidence of DGF, sCr levels at day 30, and the 1-year graft survival rate. Kidneys with IP HMP showed improved resistance and flow. Our data showed that the incidence of DGF, IGF, SGF, acute rejection, and the 1-year allograft and patient survival rates were similar between the two groups. 

Multivariate analysis of DGF incidence identified the following four significant risk factors: donor hypertension history, donor terminal sCr level, warm ischemic time, and terminal vascular resistance. HMP pressure and terminal flow did not significantly influence the rate of DGF, indicating that high pressure may not actually contribute to posttransplant renal dysfunction. Thus, increased pump perfusion pressure accompanied by improved flow rate and resistance yielded acceptable graft survival and kidney function outcomes. The exact mechanisms underlying these observations need to be more precisely determined, but improved tissue perfusion may play a role in this process. Therefore, IP may allow greater utilization of marginal kidneys that show poor initial flow and perfusion.

Table 3: Hypothermic machine perfusion of kidneys

| Variables                        | CP group (n = 40) | IP group (n = 36) | t   | P    |
|---------------------------------|------------------|------------------|-----|------|
| Initial flow (ml/min)           | 48.3 ± 10.6      | 47.4 ± 7.5       | 0.423 | 0.667 |
| Terminal flow (ml/min)          | 76.3 ± 12.7      | 85.9 ± 14.6      | 3.066 | 0.003 |
| Initial resistance (mmHg·ml⁻¹·min⁻¹) | 0.66 ± 0.13    | 0.65 ± 0.16      | 0.303 | 0.765 |
| Terminal resistance (mmHg·ml⁻¹·min⁻¹) | 0.43 ± 0.14    | 0.36 ± 0.12      | 2.327 | 0.023 |
| Trap temperature (°C)           | 4.4 ± 0.9        | 4.2 ± 0.7        | 1.073 | 0.287 |
| HMP duration (h)                | 9.2 ± 1.2        | 9.6 ± 1.9        | 1.109 | 0.279 |

Data were presented as mean ± SD. CP: Constant HMP pressure; IP: Increased HMP pressure; HMP: Hypothermic machine perfusion.

Table 4: Results of clinical assessments in the constant pressure and increased pressure groups

| Variables                      | CP group (n = 40) | IP group (n = 36) | t or χ² | P    |
|--------------------------------|------------------|------------------|---------|------|
| DGF, n (%)                     | 11 (27.5)        | 9 (25.0)         | 0.060   | 0.805 |
| IGF, n (%)                     | 12 (30.0)        | 15 (41.7)        | 1.130   | 0.412 |
| SGF, n (%)                     | 17 (42.5)        | 12 (33.3)        | 0.870   | 0.361 |
| sCr on day 30 (mg/dl), mean ± SD | 1.47 ± 0.31     | 1.39 ± 0.22      | 1.284   | 0.203 |
| Acute rejection within 1 year, n (%) | 9 (22.5)        | 7 (19.4)         | 0.110   | 0.744 |
| Acute rejection within 1 year among recipients with DGF, n (%) | 4/11 (36.4) | 3/9 (33.3) | 0.020 | 0.742 |
| Kidney function recovery time (days), mean ± SD | 18.3 ± 9.1 | 16.7 ± 8.3 | 0.798 | 0.427 |
| Kidney function recovery time among recipients with DGF (days), mean ± SD | 25.4 ± 5.1       | 20.2 ± 4.7       | 2.105   | 0.031 |
| DGF duration (days), mean ± SD | 15.6 ± 2.4       | 13.2 ± 2.6       | 1.906   | 0.046 |
| Graft survival rate at 1 year, n (%) | 35 (87.5) | 32 (88.9) | 0.040 | 0.845 |
| Patient survival rate at 1 year, n (%) | 37 (92.5) | 33 (91.7) | 0.020 | 0.880 |

Table 5: Risk factors considered in multivariable analysis of delayed graft function

| Risk factors                       | OR   | 95% CI      | P     |
|------------------------------------|------|-------------|-------|
| Donor factors                      |      |             |       |
| Age                                | 1.21 | 0.71–2.19   | 0.370 |
| Hypertension history               | 1.43 | 1.02–2.06   | 0.035 |
| Diabetes mellitus                  | 1.63 | 0.68–2.96   | 0.458 |
| Hyperlipidemia                     | 2.13 | 0.74–3.86   | 0.526 |
| Cerebrovascular disease            | 1.36 | 1.09–1.64   | 0.022 |
| Congestive heart failure           | 1.49 | 1.12–1.90   | 0.041 |
| Primary COD                        | 1.26 | 0.90–1.62   | 0.212 |
| Terminal sCr                       | 1.27 | 1.06–1.62   | 0.023 |
| Perioperative factors              |      |             |       |
| WIT                                | 3.45 | 1.97–6.37   | 0.002 |
| IP versus CP                       | 0.88 | 0.62–1.14   | 0.256 |
| Terminal flow                      | 0.79 | 0.52–1.06   | 0.059 |
| Terminal resistance                | 3.12 | 1.76–6.09   | 0.012 |
| Recipients factors                 |      |             |       |
| Age                                | 1.57 | 0.89–2.25   | 0.242 |
| BMI                                | 2.78 | 0.67–7.03   | 0.193 |
| Time on dialysis                   | 1.05 | 0.91–1.24   | 0.873 |
| Pretransplant PRA                  | 3.07 | 0.92–9.97   | 0.125 |
| HLA mismatches                     | 1.26 | 0.86–1.85   | 0.212 |

No donors had gout, and there were few donors with coronary artery disease. OR: Odds ratio; CI: Confidence interval; COD: Cause of death; sCr: Serum creatinine; WIT: Warm ischemic time; CP: Constant HMP pressure; IP: Increased HMP pressure; BMI: Body mass index; PRA: Panel-reactive antibody; HLA: Human leukocyte antigen; HMP: Hypothermic machine perfusion.
Conversely, Maathuis et al. suggested that a pressure of 30/20 mmHg might be safer than that of 60/40 mmHg. Similarly, another study reported that during HMP, a pressure of 25 mmHg was found to be better than 30 mmHg. Nevertheless, these studies were performed in a porcine kidney transplant model, and the results have not been confirmed in humans. A previous study demonstrated that pressure-mediated injury could occur in the human kidney when not optimally pumped, possibly due to suboptimal perfusion that leads to hypoxia, cell waste accumulation, and oxidative stress. These mechanisms remain to be elucidated. Our data indicate that a perfusion pressure of 40 mmHg during HMP may be better in the IP group, considering the kidney function recovery time and sCr levels on day 30 among the DGF patients. Nevertheless, the HMP pressure did not affect 1-year graft survival.

The main limitation of this study is the small number of patients included. In addition, its retrospective nature limited the amount of data that could be collected from the patients’ medical charts and prevented proper stratification of the kidneys. Furthermore, this was a single-center study. Importantly, the accuracy of single perfusion parameters in predicting transplant outcomes is limited, and those parameters should be used with caution. Moreover, in light of the retrospective nature of the study, the quality of anastomosis could not be directly evaluated, and preoperative biopsies were not necessarily available. In addition, a possible bias existed in that the kidneys for which the perfusion pressure had to be increased were actually those with predicted poor outcomes because their vasculature already showed perfusion defects and could not be easily altered. Although this is merely a supposition, it might indicate that IP is somewhat advantageous since it enables the use of unsuitable organs for transplantation. However, this difference between the two groups may impair proper comparison, and additional studies are necessary to address this issue. Nevertheless, the need to increase perfusion pressure could be used as a prognostic factor after transplantation. Finally, there were some patients with uncontrolled DCD, which may affect transplantation outcomes, but there were no significant differences between the two groups, although the proportion of uncontrolled DCD was higher in the CP group. Further studies involving a larger number of patients and longer follow-up are required to evaluate the effects of increased HMP pressure on DGF and long-term graft survival in patients receiving DCD kidneys. IP settings on expanded criteria donor kidneys should be used with caution. Biopsies and each donor’s clinical data must be critically considered when a kidney displays high resistance.

In conclusion, this study showed that the flow rate through a kidney during HMP may be improved by increasing the perfusion pressure to overcome elevated vascular resistance. Therefore, for DCD organs not performing optimally under ex vivo hypothermic perfusion after 15 min of pumping, increasing perfusion pressure may yield similar early outcomes as those obtained with organs showing optimal perfusion parameters.

**Financial support and sponsorship**

This work was supported by grants from the Fundamental Research Funds for the Central Universities (No. xjj2018091), Major Clinical Research Projects of the First Affiliated Hospital of Xi’an Jiaotong University (No. XJTU1AF-CRF-2015-005), Scientific
and Technological Breakthrough in Social Development of Shaanxi Province (No. 2016SF-246), and the National Natural Science Foundation of China (No. 81670681 and 81760137).

Conflicts of interest
There are no conflicts of interest.

References
1. Huang J, Wang H, Fan ST, Zhao B, Zhang Z, Hao L, et al. The national program for deceased organ donation in China. Transplantation 2013;96:5-9. doi: 10.1097/TP0b013e318295491.
2. Ding CG, Tai QH, Han F, Li Y, Tian XH, Tian PX, et al. Predictive score model for delayed graft function based on easily available variables before kidney donation after cardiac death. Chin Med J 2017;130:2429-34. doi: 10.4103/0366-6999.216409.
3. Dominguez-Gil B, Duranteau J, Mateos A, Núñez JR, Cheisson G, Corral E, et al. Uncontrolled donation after circulatory death: European practices and recommendations for the development and optimization of an effective programme. Transplant Int 2016;29:842-59. doi: 10.1111/tri.12734.
4. Heilman RL, Mathur A, Smith ML, Kaplan B, Reddy KS. Increasing the use of kidneys from unconventional and high-risk deceased donors. Am J Transplant 2016;16:3086-92. doi: 10.1111/aat.13867.
5. Kers J, Peters-Sengers H, Heemskerk MB, Berger SP, Betjes MG, van Zuilen AD, et al. Prediction models for delayed graft function: External validation on the Dutch prospective renal transplantation registry. Nephrol Dial Transplant 2018;33:1259-68. doi: 10.1093/ndt/gfx019.
6. Xiaoming P, Xiang H, LinJuan L, Chenguang D, Ren L. Preliminary results of transplantation with kidneys donated after cardiac death: A path of hope for organ transplantation in China. Nephrol Dial Transplant 2015;30:1590-6. doi: 10.1093/ndt/gff049.
7. Chen GD, Shiu-Chung Ko D, Wang CX, Qiu J, Han M, He XS, et al. Kidney transplantation from donors after cardiac death: An initial report of 71 cases from China. Am J Transplant 2013;13:1323-6. doi: 10.1111/ajt.12190.
8. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet 2004;364:1814-27. doi: 10.1016/S0140-6736(04)17406-0.
9. Gill J, Dong J, Eng M, Landsberg D, Dong J, et al. Pulsatile perfusion reduces the risk of delayed graft function in deceased donor kidney transplants, irrespective of donor type and cold ischemic time. Transplantation 2014;97:668-74. doi: 10.1097/TP.0000000000000367.29214.10.
10. Lodhi SA, Lamb KE, Uddin I, Meier-Kriesche HU. Pulsatile pump decreases risk of delayed graft function in kidneys donated after cardiac death. Am J Transplant 2012;12:2774-80. doi: 10.1111/j.1600-6143.2012.04179.x.
11. Yao L, Zhou H, Wang Y, Wang G, Wang W, Chen M, et al. Hypothermic machine perfusion in DCD kidney transplantation: A single center experience. Urol Int 2016;96:148-51. doi: 10.1159/000430125.
12. Moers C, Pieme J, Paul A, Ploeg RJ. Machine Preservation Trial Study Group. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2012;366:770-1. doi: 10.1056/NEJMct1111038.
13. Plata-Munoz JJ, Muthusamy A, Quiroga I, Contractor HH, Sinha S, Vaidya A, et al. Impact of pulsatile perfusion on postoperative outcome of kidneys from controlled donors after cardiac death. Transplant Int 2008;21:399-907. doi: 10.1111/j.1399-069X.2008.00685.x.
14. St Peter SD, Imber CJ, Friend PJ, Liver and kidney preservation by perfusion. Lancet 2002;359:604-13. doi: 10.1016/ S0140-6736(02)07749-8.
15. O’Callaghan JM, Morgan RD, Knight SR, Morris PJ. Systematic review and meta-analysis of hypothermic machine perfusion versus static cold storage of kidney allografts on transplant outcomes. Br J Surg 2013;100:991-1001. doi: 10.1002/bjs.9169.
16. Bathini V, McGregor T, McAlister VC, Luke PP, Sener A. Renal perfusion pump vs. cold storage for donation after cardiac death kidneys: A systematic review. J Urol 2013;189:2214-20. doi: 10.1016/j.juro.2012.11.173.
17. Joehms I, Moers C, Smits JM, Leuvenink HG, Treckmann J, Paul A, et al. The prognostic value of renal resistance during hypothermic machine perfusion of deceased donor kidneys. Am J Transplant 2011;11:2214-20. doi: 10.1111/j.1600-6143.2011.03685.x.
18. Joehms I, O’Callaghan JM, Pirenné J, Ploeg RJ. Hypothermic machine perfusion of kidneys retrieved from standard and high-risk donors. Transpl Int 2015;28:665-76. doi: 10.1111/ tri.12530.
19. Dion MS, McGregor TB, McAlister VC, Luke PP, Sener A. Hypothermic machine perfusion improves Doppler ultrasonography resistive indices and long-term allograft function after renal transplantation: A single-centre analysis. BJU Int 2015;116:932-7. doi: 10.1111/bju.12960.
20. de Vries EE, Hoogland ER, Winkens B, Snoeijis MG, van Heurn LW. Renovascular resistance of machine-perfused DCD kidneys is associated with primary nonfunction. Am J Transplant 2011;11:6265-91. doi: 10.1111/j.1600-6143.2011.03755.x.
21. Mozes MF, Skolek RB, Korf BC. Use of perfusion parameters in predicting outcomes of machine-preserved kidneys. Transplant Proc 2003;35:350-1. doi: 10.1016/j.transproceed.2003.06.058.
22. Sapa S. Banff 2013 update: Pearls and pitfalls in transplant renal pathology. Nephrology (Carlton) 2015;20 Suppl 2:2-2. doi: 10.1111/ijcp.12401.
23. Ding C, Xue W, Tian P, Ding X, Pan X, Yan H, et al. Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF. Int J Clin Pract Suppl 2015;183:8-15. doi: 10.1111/ijcp.12661.
24. Ding C, Xue W, Tian P, Ding X, Pan X, Xiang H, et al. Which is more suitable for kidney transplantation at the early post-transplantation phase in China-low dosing or standard dosing of enteric-coated mycophenolate sodium? Int J Clin Pract Suppl 2014;181:10-6. doi: 10.1111/ijcp.12401.
25. Henry SD, Guarerra JV. Protective effects of hypothermic ex-vivo perfusion on ischemia/reperfusion injury and transplant outcomes. Transplant Rev (Orlando) 2012;26:163-75. doi: 10.1016/j. trre.2011.09.001.
26. Vaziri N, Thuillier R, Favreau FD, Eugene M, Milin S, Chatature NP, et al. Analysis of machine perfusion benefits in kidney grafts: A preclinical study. J Transl Med 2011;9:15. doi: 10.1186/1479-5876-9-15.
27. Patel SK, Pankewycz OG, Weber-Shrikant E, Zachariah M, Kohli R, Nader ND, et al. Effect of increased pressure during pulsatile pump perfusion of deceased donor kidneys in transplantation. Transplant Proc 2012;44:2202-6. doi: 10.1016/j.transproceed.2012.07.109.
28. Maathuis MH, Manekeller S, van der Plaats A, Leuvenink HG. The hazards of basing acceptance of cadaveric heart allografts on pulsatile pump perfusion. Transplantation: A single-centre analysis. BJU Int 2015;116:2020-5. doi: 10.1111/bju.13130.
29. Matsui T, Nishiyama T, Kato N, Kim Y. Safety of immediate machine perfusion donor heart transplantation: A single-centre analysis. J Heart Lung Transplant 2015;34:1018-22. doi: 10.1016/j.healun.2015.06.005.
适度提高低温机械灌注压力对心脏死亡器官捐献肾移植受益的临床研究

摘要

背景：心脏死亡后器官捐献低温机械灌注（hypothermic machine perfusion，HMP）时的灌注压力和灌注流量与移植肾功能相关。研究报道提高灌注压力可以改善血管阻力和灌注流量，因此本研究的目的是观察适度提高HMP压力对心脏死亡器官捐献肾移植是否临床受益。

方法：我们回顾性地分析了自2013年9月1日至2015年8月31日期间76例首次接受肾移植的受者的资料，这76例肾脏来自于48例心脏死亡后器官捐献的供体，并均接受了HMP保存。根据是否将HMP压力从最初的30 mmHg（1 mmHg = 0.133 kPa）提高至40 mmHg分为两组，提高灌注压力组（IP组，36例）和维持灌注压力组（CP组，40例），并采用多元logistic、Cox回归分析评估是否提高HMP压力与移植肾功能延迟恢复（delayed graft function，DGF）及移植肾功能衰竭的相关性。

结果：1年移植物/患者存活率、DGF发生率、肾功能恢复时间和第30天血清肌酐水平两组相似，IP组HMP流量和血管阻力均有改善。在两组DGF患者中，IP组肾功能恢复时间（P=0.031）和DGF持续时间（P=0.046）均较CP组有改善。多元logistic回归分析提示供体高血压病史（OR: 1.43, 95% CI: 1.02–2.06, P=0.035）、供体获取前血肌酐水平（OR: 1.27, 95% CI: 1.06–1.62, P=0.023）、热缺血时间（OR: 3.45, 95% CI: 1.97–6.37, P=0.002）及HMP终末阻力指数（OR: 3.12, 95% CI: 1.76–6.09, P=0.012）均为DGF的独立危险因素。Cox回归分析提示HMP终末阻力指数（HR: 2.06, 95% CI: 1.32–3.16, P=0.002）与移植物存活率相关。

结论：适度增加HMP压力提高移植肾灌注并不影响DGF发病率和1年移植物存活率，但能缩短DGF患者肾功能恢复时间和减少DGF持续时间。